Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: Intravitreal Injection of Aflibercept

Eligibility


Inclusion Criteria: Those patients with diabetic macular edema switched to aflibercept from
bevacizumab and/or ranibizumab -

Exclusion Criteria: None

-

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Theodore Leng, MD
650-723-6995
Not Recruiting